Offering sells 8,022,500 units of one share and a warrant at $0.40
By Devika Patel
Knoxville, Tenn., Aug. 29 – TapImmune Inc. raised $709,000 in the second tranche of a $3.21 million private placement of units on Aug. 26, according to an 8-K filed Monday with the Securities and Exchange Commission. The deal raised $2.5 million on Aug. 10.
In total, the company sold 8,022,500 units of one common share and one warrant at $0.40 per unit. It sold 6.25 million units on Aug. 10 and 1,772,500 units on Aug. 26.
Each warrant is exercisable at $0.50 for five years. The strike price is identical to the Aug. 9 closing share price.
Proceeds will be used for general corporate purposes, including clinical trials and research and development.
TapImmune is a Seattle-based immunotherapy company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease.
| Issuer: | TapImmune Inc.
|
| Issue: | Units of one common share and one warrant
|
| Amount: | $3,209,000
|
| Units: | 8,022,500
|
| Price: | $0.40
|
| Warrants: | One warrant per unit
|
| Warrant expiration: | Five years
|
| Warrant strike price: | $0.50
|
| Settlement date: | Aug. 10 (for $2.5 million), Aug. 26 (for $709,000)
|
| Stock symbol: | OTCBB: TPIV
|
| Stock price: | $0.50 at close on Aug. 9
|
| Market capitalization: | $47.17 million
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
